以venetoclax为基础的治疗慢性淋巴细胞白血病的一线疗法。

Q1 Medicine

Hematology/ Oncology and Stem Cell Therapy Pub Date : 2023-05-23 DOI:10.56875/2589-0646.1039

Guru Subramanian Guru Murthy, Ehab Atallah

{"title":"以venetoclax为基础的治疗慢性淋巴细胞白血病的一线疗法。","authors":"Guru Subramanian Guru Murthy, Ehab Atallah","doi":"10.56875/2589-0646.1039","DOIUrl":null,"url":null,"abstract":"The availability of novel targeted agents has revolutionized the management of chronic lymphocytic leukemia (CLL). Both B-cell lymphoma 2 (BCL2) and Bruton tyrosine kinase (BTK) inhibitors are highly effective agents for CLL treatment. Several clinical trials have demonstrated the efficacy and safety of these agents in the management of newly diagnosed and relapsed/refractory CLL. This has led to two broad approaches in the frontline management of CLL, namely venetoclax-based time-limited therapy versus BTK inhibitor-based continuous therapy. In this review, we discussed why we consider venetoclax-based therapy as a suitable frontline option for patients with CLL.","PeriodicalId":39226,"journal":{"name":"Hematology/ Oncology and Stem Cell Therapy","volume":"16 4","pages":"346-350"},"PeriodicalIF":0.0000,"publicationDate":"2023-05-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Venetoclax-based Treatment as Frontline Therapy for Chronic Lymphocytic Leukemia.\",\"authors\":\"Guru Subramanian Guru Murthy, Ehab Atallah\",\"doi\":\"10.56875/2589-0646.1039\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"The availability of novel targeted agents has revolutionized the management of chronic lymphocytic leukemia (CLL). Both B-cell lymphoma 2 (BCL2) and Bruton tyrosine kinase (BTK) inhibitors are highly effective agents for CLL treatment. Several clinical trials have demonstrated the efficacy and safety of these agents in the management of newly diagnosed and relapsed/refractory CLL. This has led to two broad approaches in the frontline management of CLL, namely venetoclax-based time-limited therapy versus BTK inhibitor-based continuous therapy. In this review, we discussed why we consider venetoclax-based therapy as a suitable frontline option for patients with CLL.\",\"PeriodicalId\":39226,\"journal\":{\"name\":\"Hematology/ Oncology and Stem Cell Therapy\",\"volume\":\"16 4\",\"pages\":\"346-350\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-05-23\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Hematology/ Oncology and Stem Cell Therapy\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.56875/2589-0646.1039\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Hematology/ Oncology and Stem Cell Therapy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.56875/2589-0646.1039","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

摘要

新的靶向药物的可用性已经彻底改变了慢性淋巴细胞白血病(CLL)的管理。b细胞淋巴瘤2 (BCL2)和布鲁顿酪氨酸激酶(BTK)抑制剂都是治疗CLL的高效药物。一些临床试验已经证明了这些药物在新诊断和复发/难治性CLL治疗中的有效性和安全性。这导致了CLL一线治疗的两种广泛方法，即基于venetoclax的限时治疗与基于BTK抑制剂的持续治疗。在这篇综述中，我们讨论了为什么我们认为venetoclax为基础的治疗是CLL患者合适的一线选择。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Venetoclax-based Treatment as Frontline Therapy for Chronic Lymphocytic Leukemia.

The availability of novel targeted agents has revolutionized the management of chronic lymphocytic leukemia (CLL). Both B-cell lymphoma 2 (BCL2) and Bruton tyrosine kinase (BTK) inhibitors are highly effective agents for CLL treatment. Several clinical trials have demonstrated the efficacy and safety of these agents in the management of newly diagnosed and relapsed/refractory CLL. This has led to two broad approaches in the frontline management of CLL, namely venetoclax-based time-limited therapy versus BTK inhibitor-based continuous therapy. In this review, we discussed why we consider venetoclax-based therapy as a suitable frontline option for patients with CLL.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Hematology/ Oncology and Stem Cell Therapy Medicine-Hematology

CiteScore

4.30

自引率

0.00%

发文量

审稿时长

27 weeks

期刊介绍： Hematology Oncology and Stem Cell Therapy is an international, peer-reviewed, open access journal that provides a vehicle for publications of high-quality clinical as well as basic science research reports in hematology and oncology. The contents of the journal also emphasize the growing importance of hematopoietic stem cell therapy for treatment of various benign and malignant hematologic disorders and certain solid tumors.The journal prioritizes publication of original research articles but also would give consideration for brief reports, review articles, special communications, and unique case reports. It also offers a special section for clinically relevant images that provide an important educational value.